SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection

Abruzzese, Elisabetta; Luciano, Luigiana; D'Agostino, F; Trawinska, Malgorzata Monika; Pane, Fabrizio; Fabritiis, Paolo de

doi:10.4084/mjhid.2020.031

Cited by 37 publications

(45 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full-size  DOI: 10.7717/peerj.9965/ fig-4 cell-culture assays for SARS-Cov-2 (Abruzzese et al, 2020). Manidipine was found in the database of experimental results for broad set of antiviral drugs, DrugVirus.info (Andersen et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Potential COVID-19 papain-like protease PL^pro inhibitors: repurposing FDA-approved drugs

Kouznetsova

Zhang

Tatineni

et al. 2020

PeerJ

View full text Add to dashboard Cite

Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19

show abstract

Section: Discussionmentioning

confidence: 99%

Potential COVID-19 papain-like protease PL^pro inhibitors: repurposing FDA-approved drugs

Kouznetsova

Zhang

Tatineni

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…Wu et al [21] Manuscript to be reviewed It is interesting to note that several drugs with high docking energy were tested or are in experimental testing: nilotinib was active only for SARS-CoV [26]; dasatinib was confirmed to be active in cell-culture assays for MERS-CoV and SARS-CoV [27]. Dasatinib was also shown to be active against SARS-Cov-2 in clinical cases [30]. Terconazole and fluspirilene were shown to be active in cell-culture assays for SARS-Cov-2 [30].…”

Section: Discussionmentioning

confidence: 99%

“…Dasatinib was also shown to be active against SARS-Cov-2 in clinical cases [30]. Terconazole and fluspirilene were shown to be active in cell-culture assays for SARS-Cov-2 [30]. Manidipine was found in the database of experimental results for broad set of antiviral drugs, DrugVirus.info [31].…”

Section: Discussionmentioning

confidence: 99%

Peer Review #3 of "Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs (v0.1)"

2020

View full text Add to dashboard Cite

Using the crystal structure of SARS-CoV-2 papain-like protease (PL pro) as a template, we developed a pharmacophore model of functional centers of the PL pro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDAapproved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PL pro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PL pro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, Hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19

show abstract

“…Since its outbreak in China and as of June 16, 2020, the pandemic has affected approximately eight million people and has caused 434,796 deaths worldwide (6). Respiratory droplets and direct interaction with infected people or indirect interaction with fomites in their settings entail the human-to-human transmission of the virus (7). The reproduction number of this novel virus has been assessed between 1.4 and 3.9.…”

Section: Contextmentioning

confidence: 99%

“…The reproduction number of this novel virus has been assessed between 1.4 and 3.9. This means that each infection produces one to four novel infections when nobody in the community is immune, and no preventive measures are taken (7). COVID-19 is defined by flu-like symptoms with mild to severe respiratory symptoms.…”

Section: Contextmentioning

confidence: 99%

A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

Lotfali

Ghasemi

Mardani

et al. 2020

Arch Clin Infect Dis

View full text Add to dashboard Cite

: Since late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data concerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.

show abstract

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection

Abstract: no abstract available Aknowledgements: We thank professor Nathan Tubliz, dept. Biology, University of Oregon, for his insightful support.

Cited by 37 publications

References 12 publications

Potential COVID-19 papain-like protease PL^pro inhibitors: repurposing FDA-approved drugs

Potential COVID-19 papain-like protease PL^pro inhibitors: repurposing FDA-approved drugs

Peer Review #3 of "Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs (v0.1)"

A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

Contact Info

Product

Resources

About